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Abstract Glycoprotein IIb–IIIa (GPIIb–IIIa) antagonists
have the capacity to destabilize coronary thrombi and restore
vessel patency. Antagonist concentration and residence
time, which can be increased by local intracoronary (LIC)
administration, and thrombus age may be key factors that
influence thrombus stability. Light transmission aggregom-
etry was used to examine the effects of exposing human
platelet aggregates to extremely high local levels of GPIIb–
IIIa antagonists versus conventional therapeutic levels in
vitro. Freshly-formed or aged platelet aggregates were sub-
jected to GPIIb–IIIa antagonists (abciximab, eptifibatide) or
direct thrombin inhibitor bivalirudin at concentrations sim-
ulating either conventional intravenous (IV) or LIC admin-
istration. The degree of antagonist-induced disaggregation
was significantly higher using elevated (LIC) doses versus
conventional (IV) doses (60.1 % vs. 7.4 % for abciximab,
41.6 % or 45.3 % vs. 17.6 % for eptifibatide, p \ 0.01).
Bivalirudin did not promote disaggregation. Microscopy
confirmed noticeably smaller, more dispersed aggregates for
antagonist LIC treatments. Dosing at LIC levels also induced
more disaggregation than IV levels when aggregates were
aged for 30 min prior to exposure. An in vitro perfusion
model was used to simulate the fluid dynamics of IV or LIC
administration of abciximab using a microporous local drug
delivery balloon catheter such as the Atrium ClearWayTM
RX. The perfusion model resulted in more rapid thrombus
clearance with LIC dosing levels compared to IV. In sum-
mary, boosting the concentration of GPIIb–IIIa antagonists
enhances dispersal of human platelet aggregates in vitro.
These data provide a foundation for investigating increased
local concentrations of GPIIb–IIIa antagonists in patients, as
with LIC administration.
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Introduction
Platelets play a vital role in primary hemostasis. While
circulating platelets are normally quiescent, they can be
rapidly stimulated upon adherence to exposed subendo-
thelial matrix components and by soluble agonists at sites
of vascular injury. A complex interplay of adhesive inter-
actions and intracellular signaling pathways, including
granule secretion and cytoskeletal reorganization, facilitate
platelet activation and aggregation to form a platelet-rich
thrombus that arrests bleeding. Furthermore, platelet acti-
vation and aggregation contribute to the amplification of
coagulation, clot retraction, and eventual wound healing
processes [1]. The rupture of vulnerable plaque formed by
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atherosclerotic disease can lead to pathological thrombus
formation and vascular occlusion, which may manifest
dangerously as myocardial infarction in the coronary artery
or occlusive stroke as a consequence of embolization.
Pharmacological intervention directed toward platelets has
traditionally aimed to prevent platelet activation and sub-
sequent thrombosis. Platelet glycoprotein IIb–IIIa (GPIIb–
IIIa) receptor antagonists have proven to be potent
anti-platelet agents with established clinical benefit to patients
presenting with acute coronary events when either managed
medically or undergoing percutaneous coronary intervention
(PCI) [2, 3]. Numerous in vitro, ex vivo, and clinical studies
clearly outline the capability of these agents to prevent platelet
aggregation by inhibiting fibrinogen-mediated crosslinking of
activated platelets via the activated GPIIb–IIIa receptor [4–6].
Recent studies reveal that these agents may have additional
effects on platelets aggregates that have already formed, causing
them to disengage and disperse [7–11]. Previous work in our
laboratory confirmed that GPIIb–IIIa antagonists abciximab and
eptifibatide readily dispersed freshly-formed platelet
aggregates [12]. The mechanism for decreased aggregate
stability correlated with antagonist-induced dissociation of
fibrinogen from the platelet surface. The choice of antago-
nist, antagonist concentration, and age of the platelet
aggregates affected the extent of platelet disaggregation.
The current study examined the capacity for extremely
high local concentrations of abciximab and eptifibatide, as
may be achieved through local intracoronary (LIC) adminis-
tration, to disperse preformed platelet aggregates in vitro. The
influence of aggregate stability on the effects of antagonist-
induced disaggregation was also investigated by exposing
aged platelet aggregates to the antagonists at LIC levels.
Bivalirudin, a direct thrombin inhibitor, was included in these
studies as a comparator because it is approved for use as an
anticoagulant in patients with unstable angina undergoing
percutaneous coronary angioplasty with or without provi-
sional GPIIb–IIIa antagonist use. However, bivalirudin has
not been reported to act directly on platelets to disrupt pre-
formed thrombus. Lastly, an in vitro capillary perfusion model
was employed to investigate the disaggregating effects of IV
and LIC abciximab administration. This model was designed
to simulate pertinent fluid dynamic conditions and respective
local drug concentrations achieved by either standard IV
administration or by LIC delivery through the ClearWayTM
RX microporous drug delivery balloon catheter (Atrium
Medical Corporation, Hudson NH). LIC delivery offers sev-
eral potential advantages to traditional intracoronary (IC)
delivery. Traditional IC delivery utilizes a guide catheter to
infuse at the coronary ostium, limiting penetration into
occlusive thrombus and allowing the drug to follow lower
resistance pathways such as the aorta or the not-target coro-
nary artery. In contrast, the ClearWayTM RX system atrau-
matically occludes proximal blood flow at the deployment site
while delivering a therapeutic through a micropourous PTFE
membrane. The agent is delivered at high concentration
directly to a thrombus or as a distally advancing column of
fluid between the device and the thrombus (when deployed
proximally). Elevated drug levels are undiluted by upstream
flow and maintained until the balloon is collapsed. Maxi-
mizing the effective drug concentration and dwell time at the
site of delivery may enhance the potential for platelet disag-




Unless otherwise specified, materials were obtained from
Sigma-Aldrich (St. Louis, MO). D-Phenylalanyl-L-prolyl-L-
arginine chloromethyl ketone (PPACK) anticoagulant was
obtained from CalBiochem (La Jolla, CA). Eptifibatide
(Merck, West Point, PA), 2 mg/mL solution, and abcix-
imab (Eli Lilly, Indianapolis, IN), 2 mg/mL solution, were
obtained in their commercially available packaging and
formulations.
Preparation of platelets suspensions
Blood was obtained by venipuncture from normal, consenting
adult donors into PPACK anticoagulant and then centrifuged
at 135 g for 15 min to obtain platelet-rich plasma (PRP).
Remaining blood was centrifuged at 2,500g for 15 min to
obtain platelet-poor plasma (PPP). Platelet concentration in
PRP was measured with Z2 Particle Count and Size Analyzer
(Beckman Coulter, Miami, FL). Platelet count was adjusted to
2.5 9 108 platelets/mL with autologous PPP.
Disaggregation of collagen-induced aggregates
Turbidometric light transmission aggregometry (LTA) was
performed on a dual-channel lumiaggregometer (Payton
Scientific, Buffalo, NY) to quantify the extent of collagen-
induced platelet aggregation or disaggregation prior to and
following exposure to GPIIb–IIIa antagonists or respective
vehicle controls. A 500 lL aliquot of autologous PPP was
used to blank each aggregometer. Test samples of PRP were
aliquoted at 450 lL in aggregometer cuvettes. Aggregation
was induced by addition of 50 lL of 20 lg/mL type I collagen
(Chrono-Log, Havertown, PA), for a final concentration of
2 lg/mL. Aggregation was allowed to proceed for 3.5 min
following agonist addition, a point which typically repre-
sented the maximum extent of aggregation. A novel technique
was employed so that very high concentrations of antagonists
in commercially available stock solutions or appropriate
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vehicle control dilutions could be used while maintaining
physiological concentrations of platelets. For fresh aggregate
experiments, stirring was halted after 3.5 min and aggregates
were allowed to settle in the aggregometer cuvette for 1 min.
Next, 400 lL of plasma was removed from the sample and
discarded without disturbing the settled aggregates. The vol-
ume removed was replaced with 400 lL of autologous PPP,
drug, and/or vehicle control. Stirring was then immediately
resumed, and disaggregation response was recorded for
15 min. Identical methodology was employed in aged
aggregate experiments, except that samples were allowed to
settle and incubate at 37 C for 30 min, instead of 1 min,
before the 400 lL aliquot of plasma was removed and drug or
control was introduced. For each experiment, the extent of
light transmission through the sample at maximum aggrega-
tion was compared with the transmission at the resumption of
stirring to confirm the stability of the formed aggregates.
Antagonist concentrations included in these studies rep-
resented those that are clinically relevant, approximating
plasma levels following conventional intravenous adminis-
tration of the drug in question. Concentrations of drug that
might be achieved through intracoronary administration
through a typical catheter system or through an intracoronary
delivery system were also studied. The descriptive labels
used in various results figures refer to the final concentration
of the respective agent in the aggregometry cuvette. The
concentration of 2 lg/mL abciximab was chosen to
approximate the mean plasma level of abciximab immedi-
ately after a bolus IV administration [13]. Likewise, 2 lM
eptifibatide and 11 lg/mL bivalirudin were chosen based on
literature references to their respective mean plasma levels
following IV administration [14–17]. The higher concen-
tration of abciximab used was the highest concentration
possible in this experimental system, obtained by replacing
plasma removed from the aggregometry cuvette with an
equal volume of full-strength stock abciximab. Due to stock
eptifibatide low pH (*pH 5.3), the drug must be buffered
prior to intracoronary administration. The 1 mM eptifibatide
doses represent a 1:2.4 dilution of the stock eptifibatide in
autologous PPP, relevant if operators choose to buffer the
intracoronary bolus with autologous blood. The 1.6 mM
eptifibatide dose was formulated by buffering the stock ep-
tifibatide with sodium bicarbonate according to the method
of Deibele et al. [18]. The 5 mg/mL bivalirudin concentra-
tion was based on a literature reference to traditional intra-
coronary administration of bivalirudin [19].
Quantification of platelet disaggregation
Percent platelet aggregation (%PA) was determined 3.5 min
after agonist addition (%PAmax), at resumption of stirring
immediately after antagonist addition to preformed aggre-
gates (%PAresume), and at 5, 10, and 15 min after antagonist
addition to preformed aggregates (%PAtime point). The fol-
lowing calculations were made for %PA and percent platelet
disaggregation (%PD):
%PA = (distance on aggregometer tracing from 0 %
[PRP] to maximum aggregation response at given time
point)/(distance on tracing from 0 % [PRP] to 100 %
aggregation [PPP]) 9 100;
%PD ¼ ð%PAresume %PAtime pointÞ=ð%PAmaxÞ
%PD was normalized by subtracting respective vehicle
control %PD for each treatment.
Analyses of aggregates by microscopy
The wells of a 24-well cell culture plate were preloaded
with 55 lL of 10 % paraformaldehyde, pH 7.4. After dis-
aggregation extent was recorded for 15 min in LTA
experiments, the entire 500 lL sample was removed from
the aggregometer cuvette and placed into a plate well. The
sample volume was then gently pipetted three times to
achieve 1 % final paraformaldehyde concentration. Control
aliquots of untreated PRP diluted 10 % with saline, and
aggregates at maximum aggregation (3.5 min post-agonist
addition) were also prepared. Photographs of PRP or
aggregates were taken at 409 magnification within 36 h of
fixation.
Capillary perfusion aggregometry
A capillary perfusion system, detailed previously, was used
to simulate exposure of freshly-formed, platelet-rich
thrombi to either steady-state IV levels of GPIIb–IIIa
antagonists or to a LIC bolus infusion of antagonist fol-
lowed by subsequent steady-state exposure under relevant
fluid dynamic conditions [12, 20]. Briefly, whole blood
anticoagulated with PPACK was incubated with rhodamine
6G to fluorescently label platelets and leukocytes. Labeled
blood was drawn from a reservoir via syringe pump
through a rectangular capillary coated with human type III
collagen at a flow rate corresponding to normal arterial
shear stress of 40 dynes/cm2 [21, 22]. Plasma von Wille-
brand Factor (vWF) and platelets in the perfused blood
encountered and adhered to the collagen-coated surface,
stimulating formation of platelet-rich thrombus. The extent
of thrombus formation was tracked by quantifying the pixel
intensity across a series of images recorded with a fluo-
rescent videomicroscope focused on the capillary.
Following thrombus formation, precisely as the initial
volume of blood in the reservoir was depleted, blood pre-
treated with carrier control or antagonist or a bolus of stock
antagonist was added to the reservoir, thus simulating an
infusion of drug without disruption of flow. For simulations
of IV drug administration, blood pretreated with abciximab
Elevating local GPIIb-IIIa levels counteracts platelet thrombus stability 33
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at 2 lg/mL or with vehicle control was used and flow was
continued at normal arterial shear stress. For simulations of
LIC administration, a bolus of abciximab was introduced at
2 mg/mL and flow adjusted for 1 min to the unique fluid
dynamic conditions associated with intracoronary drug
administration via the ClearWayTM RX therapeutic infu-
sion catheter. This bolus was followed by a steady-state
phase with normal arterial fluid dynamics at IV abciximab
levels to simulate rapid systemic dispersal of the bolus.
The vehicle or drug treatments and the fluid dynamic
parameters used during the infusion and steady state por-
tions of the perfusion experiments are summarized in
Table 1. The wall shear stress required to replicate intra-
coronary delivery was calculated using Hagen-Poiseuille
methodology and based on theoretical ClearWayTM RX
infusion at a flow rate 10 mL/min in a 3 mm diameter
vessel in vivo. Fluid dynamic assumptions included that
flow was laminar, noncompressible, and Newtonian, and
that the viscosity of the bolus infusion was approximately
that of water (*1cP) rather than that of whole blood
(*3.6cP) [22, 23]. These assumptions account for the
delivery of drugs in aqueous vehicle with upstream blood
flow completely occluded. The wall shear stress target for
the infusion was determined to be 0.7 dynes/cm2 and was
achieved by adjusting the capillary perfusion rate based on
calculations for flow in a rectangular channel [23].
Statistical analysis
Data were analyzed using Microsoft Excel and SigmaStat
(Version 3.5, Systat Software Inc., San Jose, CA) software
packages. All values are reported as mean ± standard
deviation. Analysis of variance (ANOVA) and Student–
Newman Keuls or Holm-Sidak multiple comparison proce-
dures were used to determine statistical differences between
groups, with p \ 0.05 considered statistically significant.
Results
Collagen is one of the initial agonists encountered by platelets
during vascular injury; therefore, platelet aggregation was ini-
tiated by exposing a stirring suspension of platelets to 2 lg/mL
type I collagen and monitoring the formation and stability of
platelet aggregates using LTA. The mean aggregation response
for normal adult donors was 78.6 ± 1.6 % (n = 4). Once
maximal aggregation was achieved at 3.5 min, the freshly-
formed aggregates were exposed to pre-specified concentra-
tions of GPIIb–IIIa antagonists or respective vehicle controls
and the extent of disaggregation was measured at 5, 10 and
15 min after addition of the antagonist. The results for abcix-
imab, eptifibatide, and bivalirudin treatments are depicted in
Fig. 1. Treatment with the LIC equivalent concentration of
1.6 mg/mL abciximab resulted in a significantly higher extent
of platelet disaggregation above respective vehicle control
when compared to IV concentration of 2 lg/mL abciximab
(60.1 vs. 7.4 %, p\0.001) at 15 min (Fig. 1a). Likewise,
exposure of aggregates to either 1 mM eptifibatide or to
1.6 mM eptifibatide resulted in significantly more disag-
gregation when compared to exposure to the IV concentra-
tion of 2 lM eptifibatide at 15 min [41.6 % (1.0 mM) or
45.3 % (1.6 mM) vs. 17.6 %, p \ 0.01]. In contrast, the
extent of disaggregation using a therapeutic concentration of
11 lg/mL bivalirudin was not significantly different from
treatment with IC 5 mg/mL bivalirudin (Fig. 1a). In fact,
neither bivalirudin concentration was effective at inducing
significant amounts of disaggregation (data not shown,
p [ 0.05).
Platelet disaggregation curves for representative donors
plotted over the course of an entire experiment illustrate that
disaggregation proceeded at more rapid rates for the highest
concentrations of abciximab and eptifibatide compared to
the lowest doses of each respective agent (Fig. 1b, c). Biv-
alirudin treatment, at either concentration, consistently
resulted in little or no disaggregation above control (Fig. 1d).
Representative images of platelet aggregates fixed at the
15 min time point and visualized with brightfield micros-
copy confirmed that treatment with the elevated concentra-
tions of antagonists lead to greater aggregate dispersal when
compared to the lower doses (Fig. 1e). Conversely, biva-
lirudin treated aggregates were not visually different than
vehicle treated aggregates. Representative images are also
shown for aggregates fixed at 3.5 min following initiation of
aggregation and for unstimulated platelets.
The next series of aggregometry experiments utilized
collagen-induced platelet aggregates that had been aged for
30 min prior to introduction of the abciximab, eptifibatide,
bivalirudin, or respective vehicle controls. The persistence
Table 1 Drug concentrations and shear stress values during bolus and steady state segments of perfusion experiments






1 IV carrier control 0.1 % PBS in blood 40 0.1 % PBS 40
2 IV abciximab 2 lg/mL in blood 40 2 lg/mL 40
3 IC abciximab 2 mg/mL in PBS 0.7 2 lg/mL 40
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or bivalirudin. a Percent
disaggregation (normalized to
respective vehicle control) at
15 min post-drug addition.
Results are expressed as
mean ± SD (error bars),
n = 4, p \ 0.001, p \ 0.01
compared to lowest
experimental dose of the
respective drug. b–d
Normalized disaggregation
curves from a single
representative donor for each
drug. e Bright field microscopy
images of platelet aggregates
fixed with paraformaldehyde at
15 min post-drug addition (409
magnification). Images are from
a single donor that was
representative of an n = 4
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of stable aged aggregates after 30 min of rest, prior to
antagonist exposure, has been previously documented for
this technique, and was visually confirmed for all samples
in this study [12, 20]. Exposure of aged aggregates to the
greatly increased doses of abciximab and eptifibatide
consistently resulted in greater extents of disaggregation
above vehicle than did treatment with the low doses of the
antagonists (Fig. 2a). The overall extents of antagonist-
induced platelet disaggregation were lower than that
observed with fresh aggregates after 30 min of aging.
Representative bright field microscopy images qualita-
tively agree with the LTA data, showing more disperse
aggregates at high antagonist concentrations compared to
treatment with low concentrations of antagonist or vehicle
control (Fig. 2b). Bivalirudin treatment did not induce
platelet disaggregation above that observed for respective
vehicle controls.
The disaggregating potential of abciximab was further
investigated in a capillary perfusion system. Eptifibatide
was omitted due to buffering considerations and bivaliru-
din was not considered due to lack of disaggregating
activity in LTA experiments. Adherent, platelet-rich
thrombi were exposed to fluid dynamic conditions and drug
concentrations simulating either conventional IV adminis-
tration of the drug or LIC administration via the Clear-
WayTM RX microporous drug delivery balloon catheter.
Exposure of the preformed thrombi to both abciximab
treatment simulations resulted in significant thrombus reduc-
tion at the 5 min time point following abciximab exposure
compared to the vehicle control for no antagonist exposure
(Fig. 3a). However, the simulation of LIC abciximab treat-
ment led to significant disaggregation compared control at
3 min of exposure, whereas the extent of disaggregation for
the IV administration simulation was not significant at that
time, indicating a more rapid onset of action for the LIC
treatment. False-color images of thrombi for representative
experimental runs also suggest that abciximab treatment
induces platelet dispersal, with an earlier onset of action for
the LIC treatment regime (Fig. 3b).
Discussion
Recent investigations by our laboratory and others suggest
that GPIIb–IIIa antagonists possess the ability to disengage
pre-formed platelet aggregates [8–12, 24]. Antagonist-
induced dissociation of fibrinogen from the platelet surface
implied that these agents regulate the interaction of the
GPIIb–IIIa receptor with fibrinogen even after the initial
stages of fibrinogen binding [12]. Antagonist-mediated dis-
persal might also be affected by the underlying aggregate
stability prior to antagonist exposure. Platelet aggregates
freshly-formed in response to 5 lM ADP were more readily
dispersed by abciximab or eptifibatide than aggregates






(normalized to vehicle control)
at 15 min post-drug addition.
Results are expressed as
mean ± SD (error bars),
n = 4. b Bright field
microscopy images of platelet
aggregates fixed with
paraformaldehyde at 15 min
post-drug addition (409
magnification). Images are from
a single donor that was
representative of an n = 4
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formed by the more potent stimulation of 2 lg/mL collagen.
Furthermore, higher concentrations of both antagonists than
typically achieved following conventional IV administration
were necessary to affect collagen-induced aggregates that
had been aged for 30 min prior to antagonist exposure [12].
These interesting observations provided an impetus to fur-
ther pursue the questions of whether GPIIb–IIIa antagonist-
induced platelet aggregate instability may contribute to the
observed clinical effectiveness of these agents, and if this
newly-revealed mode of action can be exploited as an
intervention for pre-existing thrombus burden.
GPIIb–IIIa binds to fibrinogen exclusively via the fibrin-
ogen c chain, despite the fact that multiple RGD motifs are
present on fibrinogen a chains. GPIIb–IIIa can bind other
RGD-containing ligands, such as vWF, at a site that has been
proposed to be nonidentical and spatially distinct from the
fibrinogen binding locale [25]. Hu et al. utilized a surface
plasmon residence technique to evaluate models of competi-
tive inhibition between the two proposed ligand binding sites
of GPIIb–IIIa [26]. This work suggested a two-site model of
allosteric competitive inhibition between fibrinogen and
RGD-type ligands. Importantly though, while RGD-type
ligand binding influenced the association and dissociation of
fibrinogen, fibrinogen binding did not affect the association or
dissociation of RGD-type ligand. RGD ligands were able to
bind to the receptor even when fibrinogen was already bound
and induced the dissociation of fibrinogen. These observations
provide a rationale for the dissociation of platelet-bound
fibrinogen and platelet disaggregation observed following
exposure to tirofiban or lamifiban, both nonpeptide RGD
mimetics [10, 11, 27]. Structural and binding studies later
conclusively determined that the binding site of the fibrinogen
cC peptide to GPIIb–IIIa overlaps the RGD binding site and
suggested that eptifibatide, developed to mimic the KGD
sequence from the cC peptide, binds similarly to the cC pep-
tide and RGD, but enters the GPIIb–IIIa binding pocket from a
different angle [28, 29]. Eptifibatide-induced dissociation of
fibrinogen and platelet disaggregation might therefore pro-
ceed by a mechanism similar to that observed for RGD-mi
metics [10–12]. Abciximab is a chimeric monoclonal anti-
body fragment that does not directly compete with fibrinogen
for binding to GPIIb–IIIa, but is instead thought to operate
through steric hindrance or allosteric mechanisms [30, 31].
Abciximab-induced platelet disaggregation has been obser
ved in vitro by several investigators [8, 10, 11]. Although
abciximab promotes fibrinogen dissociation from the platelet
surface, the molecular basis for the dissociation is unclear at
this time [12].
In addition to the differences in the mechanisms of
receptor antagonism by abciximab and eptifibatide, other
antagonist-specific structural and pharmacological proper-
ties may influence the ability of each agent to promote
platelet disaggregation. The molecular mass of abciximab
is approximately 50 times larger than the mass of eptifi-
batide which could reduce diffusion and transport within
aggregates and thrombi. Abciximab also has a very high
affinity and low dissociation constant, with a half-life of
dissociation from the receptor of up to 4 h. Conversely,
Fig. 3 Capillary perfusion assay for platelet disaggregation following
exposure to GPIIb–IIIa antagonist abciximab. a Percent disaggrega-
tion after saline control bolus and infusion (vehicle), 2 lg/mL
abciximab bolus followed by 2 lg/mL abciximab infusion (IV), or
2 mg/mL abciximab bolus with IC equivalent fluid dynamics
followed by 2 lg/mL abciximab infusion (IC). b False color images
of rhodamine-labeled platelet thrombi before treatment infusion and
at 1, 3, and 5 min post-infusion of control or drug. a and b results are
expressed as mean ± SD (error bars). *p \ 0.05, p \ 0.01 com-
pared to vehicle. For all panels, n = 5 for vehicle, n = 6 for IV
abciximab, and n = 7 for IC abciximab
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eptifibatide is a lower affinity competitive antagonist and
rapidly dissociates from the receptor within minutes [31].
Pharmacological differences between antagonists presum-
ably led to greater extents of platelet disaggregation by
eptifibatide compared to abciximab when levels were near
IV therapeutic concentrations [12]. However, in the current
study, both abciximab and eptifibatide rapidly and sub-
stantially dissociated platelet aggregates when administered
at elevated levels simulating intracoronary administration.
The temporal dynamics of the GPIIb–IIIa/fibrinogen
interaction, as well as the dynamic changes occurring over
time in the thrombus are likely to have dramatic effects on
the efficacy of pharmacologically-based thrombus dispersal
in vivo. Parise and Phillips noted that the reversibility of
125I-fibrinogen binding to reconstituted GPIIb–IIIa recep-
tors decreased after 1 h [32]. Marguerie et al. also descri-
bed a two-phase interaction between fibrinogen and intact
platelets with an initial reversible phase followed by irre-
versible binding within 30 min [33]. Advances in intravital
microscopy and other techniques have revealed complex
spatial and temporal changes in platelet morphology and
activation during thrombus formation in flowing blood
[34–37]. An activated core of platelets consolidates and
stabilizes over time at the site of vessel injury while unac-
tivated discoid platelets form the bulk of the initial throm-
bus. The decrease in the reversibility of receptor/fibrinogen
interaction and the decreased likelihood of disrupting a
fully consolidated platelet-rich thrombus could explain
why early administration of eptifibatide has been associ-
ated with improved TIMI 3 patency before primary PCI as
compared with late (just before PCI) or no administration
[38]. Similar studies also demonstrate that early adminis-
tration of abciximab or tirofiban versus late administration
of those agents results in improved outcomes in patients
with ST Segment Elevation Myocardial Infarction
(STEMI) [39–42]. These insights led us to explore the
influence of thrombus aging on the effectiveness of
antagonist induced aggregate dispersal. Our data demon-
strate that aggregate dispersal by levels of antagonists
corresponding to local concentrations following LIC
delivery is more pronounced than that observed for IV
levels even after aggregates have been allowed to stabilize.
Therefore, LIC administration of antagonist may be more
effective therapeutically when treating patients presenting
after the onset of acute coronary symptoms related to an
occlusive event.
Recent clinical studies emphasize that novel strategies
that improve reperfusion by reducing thrombus burden and
or microembolization may result in improved clinical
outcomes. The Thrombus Aspiration during PCI in Acute
myocardial infarction Study (TAPAS) found that enhanced
reperfusion after thrombus aspiration, assessed by myo-
cardial blush grade or resolution of ST-segment elevation
at 30 days and at 1 year, significantly lowered rates of
death and major cardiac events compared to conventional
treatments [43, 44]. The current study supports the mech-
anistic rationale for positive clinical outcomes in studies
assessing the value of reperfusion strategies utilizing
intracoronary administration of GPIIb–IIIa antagonists. A
meta-analysis by Hansen et al. concluded that traditional
IC administration can improve outcomes compared to IV
administration in acute coronary syndromes (ACS) under-
going PCI, especially patients with STEMI undergoing
primary PCI [45]. A meta-analysis by Friedland et al.
included 11 randomized clinical trials comparing tradi-
tional IC and IV administration of abciximab, eptifibatide, or
tirofiban in ACS. The analysis concluded that IC adminis-
tration of GPIIb–IIIa antagonists has favorable effects on
TIMI flow, target vessel revascularization, and short-term
mortality after PCI, with no difference in rates of bleeding
[46]. The AIDA STEMI trial, with 2,065 randomized
patients, is the largest clinical trial conducted thus far
comparing intracoronary versus intravenous abciximab
administration during PCI in patients with acute STEMI
[47]. While the study confirmed the safety of intracoronary
abciximab administration, no differences in the combined
endpoint of death, reinfarction, or congestive heart failure
were observed between IV and IC administrations. How-
ever, intracoronary drug delivery was done proximally
through a guide catheter in that study, allowing portions of
the bolus to be diverted to the aorta and non-target arteries.
Drug delivered by this technique is also rapidly diluted and
transported downstream by blood flowing past the guide
catheter, reducing penetration into the targeted thrombus.
The AIDA STEMI authors’ discussion and independent
commentary cite several other possible explanations for the
lack of benefit reported in that study, including the study
being underpowered due to a lower than expected inci-
dence of the primary endpoint and differences in design
versus previous smaller-scale studies [47, 48].
The perfusion assay described in this study was included
because coronary fluid dynamics ultimately regulates the
convective and diffusive transport of both endogenous
mediators of thrombosis and exogenous therapeutic agents
to, from, and within a site of thrombosis, as well as mediate
the shear forces that naturally work against thrombus
accumulation. For this assay we chose to simulate a cath-
eter-based intracoronary delivery system designed to
maximize local drug concentration and dwell time at the
site of delivery, parameters which our earlier study
revealed were important mediators of antagonist-induced
thrombus dissolution [12]. The ClearWayTM RX micro-
porous drug delivery balloon catheter occludes the target
vessel upon infusion at the site of thrombosis prior to local
drug delivery through the microporous balloon. Fluid
dynamic and drug concentration calculations in the current
38 H. E. Speich et al.
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simulation assumed downstream blood flow was completely
occluded during drug administration, i.e. local drug con-
centration is not diluted by blood flowing past the expanded
balloon at the treatment site and drug dwell time are
maximized throughout the procedure. This study used in
vitro models to examine the effects of IIb/IIIa inhibitors on
platelet aggregation, and as such certain aspects present in
vivo (e.g. interactions with endothelial cells) may not be
captured in this model.
Prati et al. report that local delivery of abciximab
through the ClearWayTM RX system reduces thrombus
burden in ACS patients and that reperfusion, as measured
by corrected TIMI frame count, and clinical outcomes were
improved compared with abciximab delivered to the cor-
onary through a guide catheter [49]. Deibele and Gibson
detail two case reports concerning successful intracoronary
application of this technology and describe increased TIMI
grade flow and dissolution in response to intracoronary
administration of eptifibatide [50]. The recently completed
INFUSE-AMI study compared the effect IC abciximab
versus no abciximab on infarct size in in high-risk patients
with STEMI presenting early [51]. Design measures were
incorporated to isolate the effects of bolus-only abciximab,
including eliminating the 12-h post-PCI abciximab infu-
sions that were present in both IC and IV AIDA STEMI
groups and using procedural anticoagulation with biva-
lirudin without routine glycoprotein IIb/IIIa inhibition in
the control group. Additionally, the ClearWayTM Rx
catheter was used to deliver abciximab directly to the
infarct lesion site. INFUSE-AMI concluded that intracor-
onary abciximab significantly reduced the primary study
endpoint, infarct size, at 30 days in patients with anterior
STEMI reperfused early, while other indices of myocardial
reperfusion, including ST-segment resolution and myo-
cardial blush grade, were unaffected. Another multicenter
randomized study to evaluate LIC abciximab administra-
tion with the ClearWayTM RX catheter to improve out-
comes with lysis, the IC ClearLy study, is underway [52].
We observed no significant dispersal of fresh or aged
platelet aggregates in response to low or elevated concen-
trations of the direct thrombin inhibitor bivalirudin. This
result was not surprising, given that bivalirudin has not
been reported to influence the interaction between platelets
and pre-bound ligand. The ACUITY and ISAR-REACT-2
trial data support the utilization of GPIIb–IIIa antagonists in
troponin-positive patients, particularly if upstream clopido-
grel is not administered [53, 54]. In ACUITY, patients
randomized to bivalirudin alone consistently tended to
have substantially higher ischemic event rates than did
GPIIb–IIIa antagonist treated patients if clopidogrel was
initiated more than 30 min after PCI completion or not at
all [55]. These results are presumably due to bivaliru-
din acting as an anticoagulant only, without a direct,
platelet-related mechanism that targets thrombus formation
and stability.
In summary, platelet-mediated thrombus formation is a
complex and dynamic phenomenon. Recent research has
shed light on the unique contributions of blood rheology to
platelet-mediated thrombus formation, as well as brought
new emphasis on the spatial and temporal parameters that
affect arterial thrombus stability [36, 37]. The interplay
between the GPIIb–IIIa receptor, fibrinogen, and GPIIb–
IIIa antagonists, as well as the time-course of platelet
aggregate stabilization is critical for understanding how
pharmacological perturbation of preformed platelet aggre-
gates might be optimized. The current study provides in
vitro evidence for greater aggregate dispersal by LIC
equivalent concentrations of GPIIb–IIIa antagonist which
supports and helps explain why clinical studies have
reported improved reperfusion and patient outcomes when
these agents are administered via the intracoronary route
rather than intravenously.
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